Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab combination therapy in Crohn's disease: azathioprine versus methotrexate
2024-514633-38-00Phase 3Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Crohn's disease comparing Adalimumab + azathioprine with Adalimumab + methotrexate (2 arms). Primary endpoint: Endoscopic response at week 26. Planned start Aug 2024; status: authorised.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-514633-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514633-38-00.